News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sanofi (France) (SAN.PA) MS Drug Beats Avonex in Head-to-Head


11/1/2012 6:15:21 AM

Genzyme, now a Cambridge unit of French drug maker Sanofi SA, announced the publication of encouraging results from its studies of Lemtrada, its drug candidate for multiple sclerosis.

Results were published in the online edition of the medical journal Lancet. Lemtrada is currently being reviewed by European regulators, and at some point, Genzyme plans to submit a drug application for Lemtrada to the US Food and Drug Administration.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES